BioCryst Pharmaceuticals, Inc.

BCRX Healthcare Drug Manufacturers Specialty & Generic

BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024. In the quarter to June 2026, revenue grew 33.6%, EPS grew 1,450.0%, free cash flow grew 153.2% and total debt rose 15.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

7.79 0.23 −2.87%
Market cap
$2.1B
P/E
0.0×
Fwd P/E
−3.5×
Dividend yield
—
F-score
7/9
Altman Z
1.83
Beneish M
−2.27
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 6.24 0.00 0.00
P/S ratio
2.66 1.87 2.60 2.71
P/FCF ratio
33.33 4.74 7.42 6.81
P/Operating CF
38.32 5.61 (37.32) 24.39
P/B ratio
0.00 0.00 0.00 0.00
EV/Sales
3.43 2.11 3.30 3.22
EV/EBITDA
28.78 5.45 0.00 0.00
EV/FCF
42.94 5.34 9.41 8.11
Current Ratio
1.87 2.06 1.91 2.32
Net Debt/EBITDA
16.28 0.79 (0.89) 4.92
Debt/Equity
(1.73) (4.04) (1.55) (1.85)
Earnings Yield
(0.66%) 16.03% (18.17%) (14.40%)
Free Cash Flow Yield
3.00% 21.10% 13.48% 14.69%
Free Cash Flow per Share
0.19 1.39 (0.26) 0.41
Book value per Share
(1.85) (0.57) (2.29) (1.79)
Free Cash Flow
40.28 291.71 (62.19) 104.13
EV/EBIT
27.00 5.41 0.00 0.00
Other line items

Show all line items

Columns are period end dates